Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of action. Here, apoptosis of ErbB2-overexpressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and (ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein. Treating ErbB2-overexpressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline. Exposure to pAb alone reduced total ErbB2 protein, disrupting ErbB3 transactivation, leading to a marked inhibition of p-Akt; however, survivin protein levels remained unchanged and apoptosis only increased slightly. Treatment with trastuzumab alone had relatively little effect on survivin and apoptosis was unaffected. Combining lapatinib with either pAb or trastuzumab markedly downregulated survivin protein and enhanced tumor cell apoptosis. The association between the inhibition of survivin and enhanced apoptosis following the combination of ErbB2-targeted therapies provides a biological effect in order to identify therapeutic strategies that promote tumor cell apoptosis and might improve clinical response.
Introduction
Members of the type I tyrosine receptor kinase family (epidermal growth factor receptor-EGFR or ErbB1, ErbB2, ErbB3, and ErbB4) are activated in many epithelial malignancies where they play a role in regulating tumor growth, survival, and resistance to chemotherapy (Yarden and Sliwkowski, 2001 ). An extensive body of literature has established ErbB2 as a key mediator of tumor cell growth and survival, predicting a poor clinical outcome in the 25 -30% of breast cancer patients whose tumors overexpress ErbB2 or demonstrate ErbB2 gene amplification (Slamon et al., 1987; Gullick et al., 1991; Bacus et al., 1994) . Consequently, a therapeutic approach has been to block ErbB2 signaling by targeting either extracellular receptor sites with antibodies or abrogating ErbB2 autophosphorylation and receptor activation using small molecule tyrosine kinase inhibitors (Arteaga, 2003; Fry, 2003) . Trastuzumab, a humanized monoclonal antibody targeting ErbB2, induces G 0 /G 1 cell cycle arrest (Rodriguez et al., 1993; Pegram et al., 1999) in some models and apoptosis in others (Baselga et al., 1998; Moulder et al., 2001) . However, the majority of patients receiving trastuzumab as a monotherapy do not respond clinically (Cobleigh et al., 1999; Slamon et al., 2001; Vogel et al., 2002; Nagata et al., 2004) . The question arises as to whether combining a small molecule ErbB2 tyrosine kinase inhibitor with anti-ErbB2 antibodies leads to enhanced tumor cell apoptosis since these two noncross resistant approaches target distinct sites on the ErbB2 receptor. A similar strategy was employed in ErbB1-expressing tumor cell lines, where combining cetuximab, an ErbB1 monoclonal antibody, with either gefitinib or erlotinib, ErbB1 small molecule tyrosine kinase inhibitors led to enhanced antitumor effects (Huang et al., 2004; Matar et al., 2004) .
Lapatinib (GW572016), a potent small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases triggers apoptosis in ErbB2-overexpressing breast cancer cell lines, example, BT474 (Rusnak et al., 2001; Xia et al., 2002) . In the current study, lapatinib was combined with anti-ErbB2 antibodies to determine whether a combination strategy would lead to enhanced apoptosis in ErbB2-overexpressing breast cancer cells. We also explored the underlying biological effects of a combination ErbB2-targeted approach on mediators of tumor cell growth and survival. Here we show that enhanced tumor cell apoptosis following combination ErbB2-targeted therapies was most closely associated with down-regulation of survivin protein rather than inhibition of either MAPK-Erk1/2 or PI3K-Akt pathways alone. These findings provide the rationale for implementing therapeutic strategies that combine these two distinct ErbB2-targeted therapies.
Results
Combining lapatinib with anti-ErbB2 antibodies enhances apoptosis in ErbB2-overexpressing breast cancer cells BT474 cells were treated with (i) lapatinib (100 nM), (ii) trastuzumab (10 mg/ml), (iii) pAb (100 mg/ml); antisera from rabbits vaccinated with a human ErbB2 fusion protein (see Materials and methods), (iv) TA2021 (100 mg/ml); control rabbit antisera, or (v) lapatinib (100 nM) combined with either (ii), (iii), or (iv). A doseresponse curve for each component was established (data not shown). Lapatinib was studied at a lower concentration (100 nM) compared with previous studies (Rusnak et al., 2001; Xia et al., 2002 Xia et al., , 2004 in order to ascertain whether combining lapatinib with anti-ErbB2 antibodies would lead to enhanced tumor cell apoptosis. The concentration of trastuzumab (10 mg/ml) has been extensively reported to elicit antitumor activity in preclinical models. A concentration of pAb (100 mg/ml) providing similar levels of growth inhibition to trastuzumab in ErbB2-overexpressing tumor cell lines was selected (data not shown). The selectivity of pAb for ErbB2 over ErbB1 and ErbB3 was demonstrated by immunoprecipitation and Western blot analysis in BT474 cells (Figure 1a ). We were unable to detect ErbB4 in BT474 cells. Apoptosis of BT474 cells was assessed by flow cytometry and annexin V staining, an early indicator of apoptosis. Treatment with lapatinib, pAb, or trastuzumab as monotherapies resulted in a slight increase in apoptosis (Figure 1b , right upper and lower quadrants) compared with controls (DMSO, TA2021) (Figures 1b and c) . However, combining lapatinib with either pAb or trastuzumab resulted in enhanced tumor cell apoptosis compared with either treatment alone (Figures 1b  and c) . In addition, increasing the concentration of pAb by itself had relatively little impact on apoptosis (Figure 1d ). However, when combined with a fixed concentration of lapatinib (100 nM), increasing the concentration of pAb resulted in enhanced BT474 cell apoptosis (Figure 1d) . Similarly, combining lapatinib with anti-ErbB2 antibodies, particularly pAb, also enhanced apoptosis of SKBR3 cells, another ErbB2-overexpressing breast cancer cell line, although less than that observed in BT474 cells (Figure 1e ).
Laptinib and anti-ErbB2 antibodies modulate the expression of mediators of tumor cell growth and survival
To elucidate the underlying mechanism(s) by which the combination of lapatinib and anti-ErbB2 antibodies enhances tumor cell apoptosis, we examined the biological consequences of each of the treatment conditions described above, on growth and survival signaling pathways. BT474 cells were treated with lapatinib (100 nM), pAb (100 mg/ml), trastuzumab (10 mg/ml), or combinations thereof. (Figure 2a ). Lapatinib also reduced steady state levels of p-Erk1/2 and p-Akt (Figure 2b ). In contrast, pAb markedly inhibited total ErbB2 protein without affecting p-ErbB2 (Figure 2a ). Phospho-Erk1/2 and p-Akt were also markedly inhibited by pAb (Figure 2b ). In our hands, trastuzumab had less effect on total ErbB2 compared with pAb, although it slightly inhibited p-ErbB2 (Figure 2a) . Moreover, p-Erk1/2 and p-Akt were also inhibited by trastuzumab, although less than that observed with pAb ( Figure 2b ). Combining lapatinib with pAb resulted in further inhibition of pErbB2 compared with lapatinib alone (Figure 2a ). The combination of lapatinib with trastuzumab completely inhibited p-ErbB2 steady-state protein levels (Figure 2a ), in addition to inhibiting p-Erk1/2 and p-Akt. Cells treated with DMSO or TA2021 served as a controls. Increasing the concentration of pAb from 20 to 100 mg/ml and then to 200 mg/ml did not Proteins immunoprecipitated (IP) with pAb were separated by SDS-PAGE. Lane 1: IP with antibodies to ErbB2 (top row), ErbB3 (middle row), and ErbB1 (bottom row) followed by Western blot analysis using anti-ErbB2 (top row), anti-ErbB3 (middle row), and anti-ErbB1 (bottom row) specific antibodies. Lane 2: IP with pAb and then Western blot analysis using anti-ErbB2 (top row), ErbB3 (middle row), and ErbB1 (bottom row) specific antibodies. (b) BT474 were treated with (i) lapatinib (100 nM), (ii) pAb (100 mg/ml), (iii) trastuzumab (10 mg/ml), (iv) TA2021 (100 mg/ml), or (v) lapatinib combined with either pAb, trastuzumab, or TA2021 for 72 h and then apoptosis assessed by annexin V staining and flow cytometry. Dot plots are displayed with annexin V (X-axis) and 7-ADD (Y-axis) staining, the latter a viability stain that binds to the nuclear material within the cell after the membrane breaks down. (100 nM), (ii) pAb (100 mg/ml), (iii) trastuzumab (10 mg/ml), (iv) TA2021 (100 mg/ml), or (iv) lapatinib combined with either pAb, trastuzumab, or TA2021. After 72 h, apoptosis was assessed using annexin V staining and flow cytometry. All results are representative of at least three independent experiments Antitumor activity combining lapatinib and anti-ErbB2 Abs W Xia et al lead to increased inhibition of total ErbB2 protein but did result in enhanced inhibition of p-ErbB2, especially at higher concentrations of pAb ( Figure 2c ).
Although the PI3K-Akt pathway plays a role in regulating tumor cell survival, the viability of BT474 and SKBR3 cells was only slightly affected by pAb (Figure 1e ) following the combination of lapatinib and pAb was also observed in SKBR3 cells although to a lesser degree than BT474 cells.
Inhibition of p-Akt by pAb and lapatinib is associated with disruption of ErbB3 activation
ErbB3 contains six PI3K docking sites (Fedi et al., 1994; Prigent and Gullick, 1994) . However, ErbB3 lacks autokinase activity (Guy et al., 1994) , being transactivated through formation of heterodimers with other ErbB partners; ErbB2/ErbB3 heterodimers represent the most potent activator of the PI3K-Akt signaling pathway (Pinkas-Kramarski et al., 1996; Holbro et al., 2003) . The complete loss of p-Akt protein following pAb made it tempting to speculate that pAb might be disrupting ErbB3 transactivation. Steady-state p-ErbB3 protein levels in BT474 cells were completely inhibited by pAb as a monotherapy or in combination with lapatinib ( Figure 3 ). Combining lapatinib with trastuzumab also resulted in a marked inhibition of p-ErbB3 (Figure 3 ). In contrast, trastuzumab or lapatinib alone had relatively little impact on p-ErbB3. Total ErbB3 protein levels remained unchanged under all treatment conditions, and they serve as control for equal loading of protein ( Figure 3 ).
Not all quinazoline ErbB tyrosine kinase inhibitors exhibit similar effects on survival pathways
Although lapatinib and gefinitib are both 4-anilinoquinazolines, they differ in their enzymatic properties and spectrum of ErbB receptor inhibitory activity (Wood et al., 2004) . To determine whether the effects of combination ErbB-targeted therapies on survivin were generalized to other quinazoline ErbB kinase inhibitors, we treated BT474 cells with gefitinib alone (100 nM), or
ErbB2 survivin actin DMSO lapatinib (100nM) pAb (100 µg/ml) TA2021(100 µg/ml) trastuzumab (10 µg/ml) DMSO lapatinib (100nM) pAb (100 µg/ml) TA2021(100 µg/ml) trastuzumab (10 µg/ml) DMSO lapatinib (100nM) pAb (100 µg/ml) TA2021(100 µg/ml) trastuzumab (10 µg/ml) p-ErbB3 ErbB3 Figure 3 Effects of lapatinib and anti-ErbB2 antibodies on the activation state of ErbB3. BT474 cells were cultured under various treatment conditions. After 72 h, cell lysates were collected and steady-state protein levels of total ErbB3 and activated phosphoErbB3 assessed by Western blot. All results are representative of at least three independent experiments Antitumor activity combining lapatinib and anti-ErbB2 Abs W Xia et al gefitinib in combination with either pAb (100 mg/ml) or trastuzumab (10 mg/ml). In our hands, the IC 50 (based on cell proliferation) of gefitinib and lapatinib in BT474 cells are similar (data not shown). Treatment with gefitinib had little impact on BT474 cell apoptosis (Figure 4a ). Combining gefitinib with either pAb or trastuzumab increased apoptosis (Figure 4a ), although less than that achieved when combining lapatinib with either pAb or trastuzumab. Moreover, the biological effects of gefitinib, either alone or in combination with pAb or trastuzumab, differed from that observed with lapatinib. In contrast to lapatinib, gefitinib had less effect on p-ErbB2, p-Erk1/2, p-Akt, and virtually no inhibition of survivin (Figures 4b and c) . Survivin protein levels were unchanged even when the concentration of gefitinib was increased to 500 nM (data not shown). In contrast to lapatinib, combining gefitinib with either pAb or trastuzumab did not change survivin protein expression (Figure 4b ). (Johnson, 2002; Herbst et al., 2004) . Optimal clinical use of ErbB-targeted therapies therefore remains a matter of active investigation. Combining anti-ErbB2 antibodies with small molecule tyrosine kinase inhibitors is an appealing strategy since both therapies exert their anti-tumor effects via distinct mechanisms of action, which are most likely noncross resistant. Here, we combined anti-ErbB2 antibodies with lapatinib, a potent small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, in order to enhance the pro-apoptotic effects of both therapies in ErbB2-overexpressing breast cancer cells. We utilized a concentration of lapatinib (100 nM) that by itself induced only minimal apoptosis in ErbB2-overexpressing breast cancer cells in order to evaluate the effects of combining lapatinib with anti-ErbB2 antibodies. Our findings indicate that combining anti-ErbB2 antibodies with lapatinib enhances apoptosis of certain ErbB2-overexpressing breast cancer cells.
Discussion
To elucidate the mechanism(s) underlying this proapoptotic response, we focused on the biological consequences of combining lapatinib with anti-ErbB2 antibodies. At therapeutic concentrations (e.g., 1 mM), lapatinib inhibits the MAPK-Erk1/2 and PI3K-Akt signaling pathways, triggering apoptosis especially in ErbB2-overexpressing breast cancer cells such as BT474 and to a lesser extent, SKBR3 (Rusnak et al., 2001; Xia et al., 2002) . Although the exact mechanism by which Antitumor activity combining lapatinib and anti-ErbB2 Abs W Xia et al lapatinib induces tumor cell apoptosis is unknown, inhibition of survivin appears to play a key role (manuscript in preparation). Survivin, a member of the inhibitor of the apoptosis family of proteins protects tumors from programmed cell death following activation of intrinsic or extrinsic apoptotic pathways (Tamm et al., 1998; Li et al., 1999; Du et al., 2000; Verhagen et al., 2000; Marusawa et al., 2003; Song et al., 2003) . Therapeutic strategies to reduce levels of survivin in tumors might lead to spontaneous tumor cell death or synergize with the antitumor activity of cytotoxic agents. In the current report, we show that downregulation of survivin provides a stronger correlate of enhanced apoptosis in response to the combination of lapatinib and anti-ErbB2 antibodies compared with the inhibition of p-Erk1/2 and/or p-Akt. Our data differs from previous studies in hematopoietic and endothelial cells, where the regulation of survivin was directly linked to the MAPK-Erk1/2 and PI3K-Akt signaling pathways (Papapetropoulos et al., 2000; Carter et al., 2001) . Thus, while treatment with pAb alone completely inhibited p-Akt, it did not modulate expression of survivin protein and only slightly increased tumor cell apoptosis compared with the combination of pAb and lapatinib, suggesting the presence of an alternate pathway of survivin regulation in ErbB2-overexpressing breast cancer cells. In contrast, treatment conditions that maximally inhibited survivin protein (e.g., lapatinib combined with either pAb or trastuzumab) resulted in marked tumor cell apoptosis. Antibodies, especially polyclonal antisera such as pAb, dampen ErbB2 signaling by downregulating ErbB2 protein expression through receptor endocytosis (Maier et al., 1991; Park et al., 1992; Sliwkowski et al., 1999) , an activity not shared by lapatinib. Conversely, lapatinib, but not antibody therapy, potently inhibited ErbB2 activation by blocking receptor autokinase activity. The combination of lapatinib and anti-ErbB2 antibodies may result in a more effective blockade of ErbB2 signaling, including dimerization with other receptors. While inhibition of survivin appears to play a key role in mediating the enhanced pro-apoptotic effects of combination ErbB2-targeted therapies, the contribution of other factors, for example, inhibition of PI3K-Akt signaling, cannot be excluded. We compared two sources of anti-ErbB2 antibodies. The first, trastuzumab, a humanized monoclonal antibody targets a specific epitope on the ErbB2 extracellular domain. The mechanism(s) mediating the anti-tumor activity of trastuzumab appears to be multifactorial including (i) antibody-dependent cell cytotoxicity Clynes et al., 2000) , (ii) modulation of ErbB2 signaling, (iii) internalization of ErbB2 cell surface protein (Maier et al., 1991; Park et al., 1992) , (iv) reduction in proteolytic cleavage of the ErbB2 extracellular domain (Molina et al., 2001) , and (v) interference with DNA damage repair (Pietras et al., 1994) . In our hands, trastuzumab alone had relatively little effect on p-ErbB2, MAPK-Erk1/2 in BT474 cells. Trastuzumab also did not affect survivin protein expression. Consistent with other investigators, we found that treatment with trastuzumab as a monotherapy had relatively little impact on apoptosis of ErbB2-overexpressing BT474 and SKBR3 cells.
We also studied the effects of polyclonal anti-ErbB2 antibodies generated in rabbits vaccinated with a human ErbB2 fusion protein. These polyclonal antibodies appear to be specific for ErbB2 (Figure 1a) . In contrast to a monoclonal antibody like trastuzumab, polyclonal antibodies are characterized by a spectrum of binding affinities against multiple ErbB2 epitopes. Polyclonal antibodies may exert distinct biological effects depending upon which extracellular domain binding sites they recognize. For example, trastuzumab does not block the formation of ErbB2-containing heterodimers (Agus et al., 2002) . This has potential clinical relevance since ErbB2/ErbB3 heterodimers potently activate the PI3K-Akt survival/resistance pathway (Pinkas-Kramarski et al., 1996; Holbro et al., 2003) . ErbB3, which lacks autokinase activity, is dependent upon an ErbB receptor partner, notably ErbB2, for its transactivation (Guy et al., 1994; Alimandi et al., 1995) . In our hands, pAb but not trastuzumab markedly downregulated ErbB2 protein (Figure 2a ), which would likely have an impact on the formation of ErbB2/ErbB3 heterodimers, providing a possible explanation for the potent inhibitory effect of pAb on p-ErbB3 (Figure 3 ) and p-Akt protein (Figure 2c ). Although inhibition of p-Akt in response to pAb by itself only slightly increased tumor cell apoptosis, it still might be sufficient to sensitize tumors to the killing effects of conventional cytotoxic agents, which are generally less effective in tumors that overexpress p-Akt (Brognard et al., 2001; Tenzer et al., 2001; Thakkar et al., 2001) .
Our findings are consistent with those recently reported in which enhanced anti-tumor activity against ErbB1-expressing tumor cells was achieved when cetuximab, a humanized anti-ErbB1 monoclonal antibody, was combined with either gefitinib or erlotinib, two small molecule ErbB1 tyrosine kinase inhibitors. Biological correlates of this ErbB1 combination approach included increased inhibition of p-ErbB1, p-Erk1/2, and p-Akt (Huang et al., 2004; Matar et al., 2004) . Geftinib and lapatinib are both quinazolines. Beyond structural similarities, the two compounds have different enzymatic profiles (Wood et al., 2004) . Although gefitinib was developed as an ErbB1 tyrosine kinase inhibitor, its IC 50 in BT474 cells is similar to that of lapatinib (Moulder et al., 2001) . However, when used alone, gefitinib (100 nM) had very little effect on survivin or apoptosis. Moreover, adding gefitinib to anti-ErbB2 antibodies did not modulate survivin or lead to enhanced apoptosis to the same degree as lapatinib. This might partially explain the lack of clinical benefit when gefitinib was combined with trastuzumab in patients with ErbB2-overexpressing breast cancers (Arteaga et al., 2004) . These biological differences on mediators of tumor cell survival may be clinically relevant, as preliminary data in a phase I trial combining lapatinib with trastuzumab shows promising clinical activity in breast cancer patients whose disease progressed on prior trastuzumab therapy (Burris et al., 2004) . Therefore, when selecting the components of an ErbB-targeted therapeutic cocktail, consideration should be given to the biological effects of the targeted agents on mediators of tumor cell survival.
Small molecule inhibitors have an advantage over antibodies in their ability to inhibit multiple signaling pathways, especially at plasma concentrations that are readily achieved in the clinic. This has relevance since the survival of most epithelial tumors is dependent upon redundant pathways. Lapatinib likely modulates targets other than full-length ErbB1 and ErbB2. In this regard, we recently showed that lapatinib effectively inhibited signaling transduction through the truncated ErbB2 receptor, p95
ErbB2 (Xia et al., 2004) . Similarly, antibodies possess biological activities not shared by small molecule inhibitors like lapatinib. For example, although antibodies do not inhibit signaling through p95 ErbB2 , they reduce truncation by inhibiting proteolytic cleavage of full-length ErbB2 (Molina et al., 2001) . Since expression of p95
ErbB2 has been linked to disease progression in breast cancer (Christianson et al., 1998; Molina et al., 2002) , reducing the formation of, and signaling via p95
ErbB2 is one example where a combination strategy might impact on disease progression.
Finally, ErbB receptors are also expressed on normal tissue, which might explain the toxicity profile associated with these agents, especially at higher concentrations. The ability to induce tumor cell apoptosis by combining lapatinib at low concentrations, with therapeutic antibodies, might reduce toxicity without compromising efficacy. Elucidating the biologic effects of combining different ErbB2-targeted therapies provides the scientific rationale for maximizing the benefit of this approach in the clinic.
Materials and methods

Cell lines and reagents
ErbB2-overexpressing human breast cancer cell lines, BT474 and SKBR3, were obtained from the American Type Culture Collection (Manassas, VA, USA). BT474 and SKBR3 cells were grown in RPMI 1640 supplemented with L-glutamine, 10% FBS (Hyclone). Cells were maintained in a humidified atmosphere of 5% CO 2 at 371C. Antihuman survivin antibody was from RD System (Minneapolis, MN, USA). Antimouse IgG was from Rockland (Gilbertsville, PA, USA). Antibodies to phosphotyrosine and actin were purchased from SigmaAldrich (St Louis, MO, USA). Anti-ErbB1 (Ab -12) and antic-ErbB2 (Ab -11) antibodies were from Neo Markers (Union City, CA, USA). Anti-phospho-Akt (Ser 437) was from Cell Signaling Technology, Inc. (Beverly, MA, USA). Anti-Akt1/2, anti-phospho-Erk1/2, anti-Erk1, and anti-Erk2 antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Trastuzumab was purchased from Genentech, Inc. (South San Francisco, CA, USA). Guava PCA 96 Nesin kit was purchased from Guava Technologies Inc. (Hayward, CA, USA). SuperSignal West Femto Maximum Sensitivity Substrate was from Pierce (Rockford, IL, USA). Protein G agarose was purchased from Boehringer Mannheim (Germany). GW572016, N-{3-Chloro-4-[(3-fluorobenzyl)oxy]-phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, was synthesized as previously described . Lapatinib for cell culture work was dissolved in DMSO (Xia et al., 2002) .
ErbB2 fusion protein vaccination and antibody isolation
Anti-ErbB2 antibodies (pAb) were generated using GSK ErbB2 vaccine, which is a recombinant purified protein produced in CHO cells composed of both the extracellular domain (ECD) of ErbB2/neu and the carboxyl terminal autophosphorylation portion of the intracellular domain (ICD). Four New Zealand female rabbits were vaccinated intramuscularly at 3-week intervals with 100 mg of dErbB2 protein formulated in a liposomal adjuvant containing 50 mg 3D-MPL (Corixa, Seattle, WA, USA), 50 mg OS21 (Antigenics, New York, NY, USA) admixed with 500 mg CpG Oligonucleotide 2006 (Coley Pharmaceutical Group, Wellesley, MA, USA). A booster injection was given at day 161 and sera were collected 14 days later. The IgG fraction was purified using protein A sepharose. Preimmune purified Ig was used as a negative control assay (pool of two naı¨ve rabbits).
Annexin V staining and flow cytometry
Cells were treated in six-well plates with lapatinib at concentrations as indicated in the figure legends. After harvesting the cells with trypsin-EDTA, 5000 cells in 50 ml were sampled on 96-well microplates. The cells were stained directly in the microplate with Annexin V-PE and Nexin 7-AAD in 1 Â Nexin Buffer in a 200 ml final reaction volume. After incubating for 20 min at room temperature, the reaction samples were ready to be acquired in the Guava PCA-96-system (Guava Technology Inc., Hayward, CA, USA).
IP and Western blot analysis
Whole-cell extracts were prepared by scraping cells off Petri dishes, washing the cell pellet twice in phosphate buffered saline (PBS), and then resuspending the pellet in two-packedcell volumes of RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.25% (w/v) deoxycholate, 1% NP-40, 5 mM sodium orthovanadate, 2 mM sodium fluoride, and a protease inhibitor cocktail). Protein concentrations were determined using a modification of the Bradford method (Bio-Rad Labs, Hercules, CA, USA). The cell lysate was cleared by centrifugation, and ErbB1, ErbB2, and ErbB3 were separately immunoprecipitated from 200 mg of the lysate with 3 mg of anti-ErbB1 (Ab-13, Neo Markers), anti-ErbB2 (Ab-11, Neo Markers), anti-ErbB3 (C-17, Santa Cruz Biotechnology) antibodies, or 5 mg of pAb and 20 ml of protein A þ G-Sepharose. The immunoprecipitates were separated by 4 -15% gradient SDSpolyacrlyamide agarose gel electrophoresis (SDS-PAGE), and ErbB receptors were detected by Western blot with antiErbB receptor antibodies. Steady-state levels of survivin, ErbB2, pTyr, total Erk1/2 and activated Erk1/2 (p-Erk), as well as total Akt protein and activated Akt (p-Akt) protein were assessed by Western blot. For Western blot, equal amounts of proteins were resolved by either 7.5% or 4 -15% gradient SDS-PAGE under reducing conditions. Proteins were transferred to Immobilon-P or nitrocellulose membranes. Efficiency and equal loading of proteins was evaluated by Ponceau S staining. Membranes were blocked for 1 h in TBS (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2.7 mM KCl) containing 4% (w/v) low-fat milk or 3% BSA (w/v). Membranes were then probed with specific antibodies recognizing target proteins, which were visualized with the SuperSignal West Femto Maximum sensitivity substrate kit (Pierce) or Odyssey Infrared Imaging System (LI-COR, Lincoln, NE, USA).
